Survodutide Phase 3 Trial Targets Weight Loss in Diabetics

Millions worldwide grapple with overweight or obesity, often co-occurring with Type 2 Diabetes Mellitus (T2DM), a combination that significantly increases health risks. While various treatments exist, there remains a critical need for highly effective and safe options that address both conditions simultaneously. This Phase 3 clinical trial was designed to rigorously assess whether survodutide can induce significant weight loss and improve metabolic health in adults living with both overweight/obesity and Type 2 Diabetes.

While the specific efficacy and safety results from this Phase 3 trial are currently pending public release, the study was meticulously designed to quantify the impact of survodutide on body weight and metabolic health. The primary endpoint will measure the percentage change in body weight from baseline over the 76-week treatment period, aiming to demonstrate a statistically significant and clinically meaningful reduction compared to placebo. Researchers anticipated that survodutide could achieve substantial weight loss, potentially in the range of 5% to 15% or more, based on prior research with similar compounds. Secondary endpoints are expected to include improvements in glycemic control (e.g., HbA1c levels) and other cardiometabolic markers, which are crucial for this patient population. The core objective was to determine if survodutide could induce a superior percentage reduction in body weight compared to placebo in 755 participants with overweight or obesity and Type 2 Diabetes Mellitus over 76 weeks.